Background: The risk of tamoxifen related endometrial neoplasm has been confirmed by multiple studies. Case: The case of a 65-year-old multiparous postmenopausal woman who received tamoxifen 20 mg daily for 4 years after the treatment of breast cancer is presented. Four years after initiation of tamoxifen treatment, the patient developed a malignant mixed mesodermal tumor (MMMT) of the uterus. She was treated surgically with adjuvant radiotherapy. Conclusions: The benefits of adjuvant tamoxifen therapy outweigh the increased risk of uterine cancer, but the risk of uterine cancer continues for years after tamoxifen is discontinued. (J GYNECOL SURG 28:418)
Get full access to this article
View all access options for this article.
References
1.
GeraciP, MaggioS, AdragnaFet al.Uterine sarcomas. A retrospective study of 17 cases. Eur J Gynaecol Oncol, 1988; 9:497.
2.
MarthC, WindbichlerG, PetruEet al.Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol, 1997; 64:121.
3.
BergmanL, BeelenMLR, GalleeMP, HollemaH, BenraadtJ, van LeeuwenFE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet, 2000; 356:881.
4.
CurtisRE, FreedmanMD, ShermanME, FraumeniJFRJr. Risk of malignant mixed Müllerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst, 2004; 96:70.
5.
Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998; 351:1451.
6.
BaumM, BudzarAU, CuzickJ, ForbesJ, HoughtonJH, KlijnJGet al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet, 2002; 359:2131published erratum appears in Lancet 2002;360:1520
7.
Christin-MaitreS, Chabbert-BuffetN, BouchardP. Action of estrogen and progesterone at the cellular level. FraserIS, JansenRPS, LoboRA, WhiteheadMI. Estrogens and progestogens: New York: Churchill Livingstone, 1998; 119.
8.
WebbP, LopezGN, UhtRM, KushnerPJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell specific estrogen-like effects of antiestrogens. Mol Endocrinol, 1995; 9:443.
9.
NephewKP, PolekTC, AkcaliKC, KhanSA. The antiestrogen tamoxifen induces c-fos and jun-B but not c-jun or jun-D protooncogenes in the rat uterus. Endocrinology, 1993; 133:419.
10.
SartorBM, SartorO, FlandersKC. Analogous tamoxifen and estrogen effects on transforming growth factor-beta 1 and 2 in the rat uterus. Reprod Toxicol, 1995; 9:225.
11.
ClarkDA. Cytokines and uterine bleeding. AlexanderNJ, d'ArcanguesC. Steroid hormones and uterine bleeding. Washington: AAAS Press, 1992; 263.
12.
MouritsMJE, HollemaHI, WillemsePHBI, de VriesEGEI, AaldersJG, van der ZeeAGJ. Adenosarcoma of the uterus following treatment for breast cancer. Int J Gynecol Cancer, 1998; 8:168.
13.
PongraczK, PathakDN, NakamuraT, BurlingameAL, BodellWJ. Activation of the tamoxifen derivative metabolite E to form DNA adducts: Comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res, 1995; 55:3012.
14.
BergmanL, BeelenMLR, GalleeMPW, HollemaH, BenraadtJ, van LeeuwenFE. Comprehensive cancer centers ALERT group risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet, 2000; 356:881.
15.
FergusonSE, SoslowRA, AmsterdamA, BarakatRR. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol, 2006; 101:322.
